Taro Terminates License and Co-Development Agreement with NovaBiotics for Novexatin

 Taro Terminates License and Co-Development Agreement with NovaBiotics for Novexatin

Taro Terminates License and Co-Development Agreement with NovaBiotics for Novexatin

Shots:

  • The termination is based on results from P-IIb study, assessing Novexatin vs PBO, which was unable to meet a main goal of study under FDA guidelines with no superiority over PBO
  • In 2013, Taro entered into license and co-development agreement with NovaBiotics for its novel antifungal peptide Novexatin
  • Novexatin is a fast-acting topical drug candidate currently evaluated in P-IIb study for the treatment of fungal nail infections (onychomycosis)

Click here to read full press release/ article | Ref: Taro Pharmaceuticals  | Image: Taro

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post